Genomic Sequencing Procedure Microcosting Analysis and Health Economic Cost-Impact Analysis: A Report of the Association for Molecular Pathology

Journal of Molecular Diagnostics

Volumn 18, Issue 3, 2016, Pages 319-328

  Sabatini, Linda M ^a,b   Mathews, Charles ^c   Ptak, Devon ^c   Doshi, Shivang ^c   Tynan, Katherine ^d   Hegde, Madhuri R ^a,e   Burke, Tara L ^a   Bossler, Aaron D ^a,f  

^a Association for Molecular Pathology   (United States)

^b NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^c Boston Healthcare Associates   (United States)

^d Tynan Consulting   (United States)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; BIOLOGICAL MARKER;

ARTICLE; BUDGET; COST BENEFIT ANALYSIS; COST CONTROL; DIAGNOSTIC VALUE; DNA DETERMINATION; GENE SEQUENCE; GENETIC SCREENING; GENOMIC SEQUENCING PROCEDURE; HOSPICE CARE; HUMAN; INFORMATION PROCESSING; INFORMATION SCIENCE; LABORATORY TEST; MEDICARE; MENTAL DISEASE; MOLECULAR PATHOLOGY; NON SMALL CELL LUNG CANCER; PATIENT CARE; PERCEPTION DEAFNESS; PROGRESSION FREE SURVIVAL; REIMBURSEMENT; SEQUENCE ANALYSIS; CARCINOMA, NON-SMALL-CELL LUNG; COST; DNA SEQUENCE; ECONOMIC MODEL; ECONOMICS; EXOME; GENETICS; GENOMICS; HEALTH CARE COST; HEARING LOSS, SENSORINEURAL; HIGH THROUGHPUT SEQUENCING; LUNG NEOPLASMS; NEURODEVELOPMENTAL DISORDERS; PROCEDURES;

BIOMARKERS; CARCINOMA, NON-SMALL-CELL LUNG; COSTS AND COST ANALYSIS; EXOME; GENOMICS; HEALTH CARE COSTS; HEARING LOSS, SENSORINEURAL; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; LUNG NEOPLASMS; MODELS, ECONOMIC; NEURODEVELOPMENTAL DISORDERS; SEQUENCE ANALYSIS, DNA;

EID: 84963964173     PISSN: 15251578     EISSN: 19437811     Source Type: Journal    
DOI: 10.1016/j.jmoldx.2015.11.010     Document Type: Review

References (34)

1. I. Schrijver, N. Aziz, D.H. Farkas, M. Furtado, A.F. Gonzalez, T.C. Greiner, W.W. Grody, T. Hambuch, L. Kalman, J.A. Kant, R.D. Klein, D.G. Leonard, I.M. Lubin, R. Mao, N. Nagan, V.M. Pratt, M.E. Sobel, K.V. Voelkerding, and J.S. Gibson Opportunities and challenges associated with clinical diagnostic genome sequencing: a report of the Association for Molecular Pathology J Mol Diagn 14 2012 525 540
2. A. Ankala, C. da Silva, F. Gualandi, A. Ferlini, L.J. Bean, C. Collins, A.K. Tanner, and M.R. Hegde A comprehensive genomic approach for neuromuscular diseases gives a high diagnostic yield Ann Neurol 77 2015 206 214
3. L.M. Sholl, D.L. Aisner, M. Varella-Garcia, L.D. Berry, D. Dias-Santagata, I.I. Wistuba, H. Chen, J. Fujimoto, K. Kugler, W.A. Franklin, A.J. Iafrate, M. Ladanyi, M.G. Kris, B.E. Johnson, P.A. Bunn, J.D. Minna, and D.J. Kwiatkowski Multi-institutional oncogenic driver mutation analysis in lung adenocarcinoma: the lung cancer mutation consortium experience J Thorac Oncol 10 2015 768 777
4. D.B. Johnson, K.H. Dahlman, J. Knol, J. Gilbert, I. Puzanov, J. Means-Powell, J.M. Balko, C.M. Lovly, B.A. Murphy, L.W. Goff, V.G. Abramson, M.A. Crispens, I.A. Mayer, J.D. Berlin, L. Horn, V.L. Keedy, N.M. Reddy, C.L. Arteaga, J.A. Sosman, and W. Pao Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel Oncologist 19 2014 616 622
5. S.D. Sullivan, J.A. Mauskopf, F. Augustovski, J. Jaime Caro, K.M. Lee, M. Minchin, E. Orlewska, P. Penna, J.M. Rodriguez Barrios, and W.Y. Shau Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force Value Health 17 2014 5 14
6. D.T. Miller, M.P. Adam, S. Aradhya, L.G. Biesecker, A.R. Brothman, N.P. Carter, D.M. Church, J.A. Crolla, E.E. Eichler, C.J. Epstein, W.A. Faucett, L. Feuk, J.M. Friedman, A. Hamosh, L. Jackson, E.B. Kaminsky, K. Kok, I.D. Krantz, R.M. Kuhn, C. Lee, J.M. Ostell, C. Rosenberg, S.W. Scherer, N.B. Spinner, D.J. Stavropoulos, J.H. Tepperberg, E.C. Thorland, J.R. Vermeesch, D.J. Waggoner, M.S. Watson, C.L. Martin, and D.H. Ledbetter Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies Am J Hum Genet 86 2010 749 764
7. B.B. Blanchfield, J.J. Feldman, J.L. Dunbar, and E.N. Gardner The severely to profoundly hearing-impaired population in the United States: prevalence estimates and demographics J Am Acad Audiol 12 2001 183 189
8. J.P. Wisnivesky, D. Yankelevitz, and C.I. Henschke Stage of lung cancer in relation to its size: part 2. Evidence Chest 127 2005 1136 1139
9. Centers for Disease Control and Prevention Prevalence of autism spectrum disorder among children aged 8 years - autism and developmental disabilities monitoring network, 11 sites, United States, 2010 Morb Mortal Wkly Rep Surveill Summ 63 2014 1 21
10. D.S. Ettinger, D.E. Wood, W. Akerley, L.A. Bazhenova, H. Borghaei, D.R. Camidge, and et al. Non-small cell lung cancer, version 6.2015 J Natl Compr Canc Netw 13 2015 515 524
11. E.A. Collisson, J.D. Campbell, A.N. Brooks, A.H. Berger, W. Lee, J. Chmielecki, and et al. Comprehensive molecular profiling of lung adenocarcinoma Nature 511 2014 543 550
12. M. Vera-Llonch, D. Weycker, A. Glass, S. Gao, R. Borker, B. Barber, and G. Oster Healthcare costs in patients with metastatic lung cancer receiving chemotherapy BMC Health Serv Res 11 2011 305
13. F.A. Shepherd, J. Rodrigues Pereira, T. Ciuleanu, E.H. Tan, V. Hirsh, S. Thongprasert, D. Campos, S. Maoleekoonpiroj, M. Smylie, R. Martins, M. van Kooten, M. Dediu, B. Findlay, D. Tu, D. Johnston, A. Bezjak, G. Clark, P. Santabárbara, and L. Seymour Erlotinib in previously treated non-small-cell lung cancer N Engl J Med 353 2005 123 132
14. B.J. Solomon, T. Mok, D.W. Kim, Y.L. Wu, K. Nakagawa, T. Mekhail, E. Felip, F. Cappuzzo, J. Paolini, T. Usari, S. Iyer, A. Reisman, K.D. Wilner, J. Tursi, and F. Blackhall First-line crizotinib versus chemotherapy in ALK-positive lung cancer N Engl J Med 371 2014 2167 2177
15. N. Hanna, F.A. Shepherd, F.V. Fossella, J.R. Pereira, F. De Marinis, J. von Pawel, U. Gatzemeier, T.C. Tsao, M. Pless, T. Muller, H.L. Lim, C. Desch, K. Szondy, R. Gervais, Shaharyar, C. Manegold, S. Paul, P. Paoletti, L. Einhorn, and P.A. Bunn Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy J Clin Oncol 22 2004 1589 1597
16. M.E. Stokes, C.E. Muehlenbein, M.D. Marciniak, D.E. Faries, S. Motabar, T.W. Gillespie, J. Lipscomb, K.B. Knopf, and D.P. Buesching Neutropenia-related costs in patients treated with first-line chemotherapy for advanced non-small cell lung cancer J Manag Care Pharm 15 2009 669 682
17. N.M. Kuderer, D.C. Dale, J. Crawford, L.E. Cosler, and G.H. Lyman Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients Cancer 106 2006 2258 2266
18. T.A. Burke, T. Wisniewski, and F.R. Ernst Resource utilization and costs associated with chemotherapy-induced nausea and vomiting (CINV) following highly or moderately emetogenic chemotherapy administered in the US outpatient hospital setting Support Care Cancer 19 2011 131 140
19. G. Dranitsaris, J. Maroun, and A. Shah Severe chemotherapy-induced diarrhea in patients with colorectal cancer: a cost of illness analysis Support Care Cancer 13 2005 318 324
20. G.A. Brooks, L. Li, H. Uno, M.J. Hassett, B.E. Landon, and D. Schrag Acute hospital care is the chief driver of regional spending variation in Medicare patients with advanced cancer Health Aff (Millwood) 33 2014 1793 1800
21. R. Rosell, E. Carcereny, R. Gervais, A. Vergnenegre, B. Massuti, E. Felip, and et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial Lancet Oncol 13 2012 239 246
22. A.T. Shaw, D.W. Kim, K. Nakagawa, T. Seto, L. Crinó, M.J. Ahn, T. De Pas, B. Besse, B.J. Solomon, F. Blackhall, Y.L. Wu, M. Thomas, K.J. O'Byrne, D. Moro-Sibilot, D.R. Camidge, T. Mok, V. Hirsh, G.J. Riely, S. Iyer, V. Tassell, A. Polli, K.D. Wilner, and P.A. Jänne Crizotinib versus chemotherapy in advanced ALK-positive lung cancer N Engl J Med 368 2013 2385 2394
23. D.D. Mafong, E.J. Shin, and A.K. Lalwani Use of laboratory evaluation and radiologic imaging in the diagnostic evaluation of children with sensorineural hearing loss Laryngoscope 112 2002 1 7
24. J.W. Lin, N. Chowdhury, A. Mody, R. Tonini, C. Emery, J. Haymond, and J.S. Oghalai Comprehensive diagnostic battery for evaluating sensorineural hearing loss in children Otol Neurotol 32 2011 259 264
25. D.A. Preciado, L. Lawson, C. Madden, D. Myer, C. Ngo, J.K. Bradshaw, D.I. Choo, and J.H. Greinwald Improved diagnostic effectiveness with a sequential diagnostic paradigm in idiopathic pediatric sensorineural hearing loss Otol Neurotol 26 2005 610 615
26. A. Sharma, M.N. Ruscetta, and D.H. Chi Ophthalmologic findings in children with sensorineural hearing loss Arch Otolaryngol Head Neck Surg 135 2009 119 123
27. Joint Committee on Infant Hearing Year 2007 position statement: principles and guidelines for early hearing detection and intervention programs Pediatrics 120 2007 898 921
28. G.B. Schaefer, and N.J. Mendelsohn Clinical genetics evaluation in identifying the etiology of autism spectrum disorders: 2013 guideline revisions Genet Med 15 2013 399 407
29. Y. Li, L.A. Bare, R.A. Bender, J.J. Sninsky, L.S. Wilson, J.J. Devlin, and F.M. Waldman Cost effectiveness of sequencing 34 cancer-associated genes as an aid for treatment selection in patients with metastatic melanoma Mol Diagn Ther 19 2015 169 177
30. L. Nadauld, S.B. Van Norman, G. Fulde, J.G. Dermott, D. Newman, A.M. Butler, B.P. Tudor, H. Gilbert, K. Yin Lin, G. Stone, J.M. Ford, and D.S. Haslem Precision medicine to improve survival without increasing costs in advanced cancer patients. American Society of Clinical Oncology Meeting J Clin Oncol 33 Suppl 2015 Abstract e17641
31. ACMG Board of Directors Clinical utility of genetic and genomic services: a position statement of the American College of Medical Genetics and Genomics Genet Med 17 2015 505 507
32. Williams M, Bock J, Faucett A, Smith-Packard B, Wagner M, Williams J: Quantification of the diagnostic odyssey in patients referred for whole genome sequencing. 2013 American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting. 2013, Abstract 260.
33. V. Shashi, A. McConkie-Rosell, B. Rosell, K. Schoch, K. Vellore, M. McDonald, Y.H. Jiang, P. Xie, A. Need, D.B. Goldstein, and D.G. Goldstein The utility of the traditional medical genetics diagnostic evaluation in the context of next-generation sequencing for undiagnosed genetic disorders Genet Med 16 2014 176 182
34. S.E. Soden, C.J. Saunders, L.K. Willig, E.G. Farrow, L.D. Smith, J.E. Petrikin, J.B. LePichon, N.A. Miller, I. Thiffault, D.L. Dinwiddie, G. Twist, A. Noll, B.A. Heese, L. Zellmer, A.M. Atherton, A.T. Abdelmoity, N. Safina, S.S. Nyp, B. Zuccarelli, I.A. Larson, A. Modrcin, S. Herd, M. Creed, Z. Ye, X. Yuan, R.A. Brodsky, and S.F. Kingsmore Effectiveness of exome and genome sequencing guided by acuity of illness for diagnosis of neurodevelopmental disorders Sci Transl Med 6 2014 265ra168